ARTICLE | Politics & Policy

Eisai 'outraged' by NHS decision on Cancer Drugs Fund

January 9, 2015 3:05 AM UTC

Eisai Co. Ltd. (Tokyo:4523) said NHS England removed breast cancer drug Halaven eribulin mesylate from the Cancer Drugs Fund (CDF), making it the first disclosed drug to lose CDF coverage. The fund is intended to give patients access to drugs that would not otherwise be available on the NHS.

Eisai said the decision used a "flawed and inconsistent methodological process" that does not acknowledge the product's overall survival benefit for patients. "We are outraged," said Gary Hendler, president and CEO, Eisai EMEA, and president, Eisai Oncology Global Business Unit. ...